Will Besudil Mesylate Tablets be included in medical insurance in 2025?

As of 2025, Belumosudil mesylate tablets (Belumosudil) have been officially approved for marketing in mainland China and included in the National Reimbursement Directory for the treatment of chronic graft-versus-host disease (cGVHD) patients aged 12 and above who have poor response to glucocorticoids or other systemic treatments. This move marks a further improvement in the country's drug accessibility in the field of rare disease treatment, providing more affordable treatment options for many patients with refractory cGVHD.

Besudil is a small molecule inhibitor targetingROCK2 kinase. It has a unique mechanism in immune regulation. It can reduce the levels of pro-inflammatory cytokines and improve the balance of immune cells, thereby effectively alleviating the multi-system damage of GVHD. As a new type of immunomodulator, its research and development was originally based on the European and American markets, and it was only approved for use in China in recent years. Its inclusion in the medical insurance catalog means that the government recognizes its therapeutic value and is willing to reduce the financial burden on patients through the medical insurance payment mechanism.

The common specifications of Besudil currently on the market are0.2g × 30 tablets. The original selling price is relatively high, with the price of each box ranging from RMB 10,000 to RMB 20,000. However, after being included in medical insurance, some patients can have their drug costs reimbursed on a proportional basis if they meet the medical insurance drug standards, which is of great significance to chronic GVHD patients who have been taking the drug for a long time. It should be noted that medical insurance reimbursement often comes with conditions for use, such as diagnosis criteria, severity of illness, or previous treatment failure records. Therefore, when applying for medication, a clear diagnosis and advice must be issued by a specialist at a medical institution.

In addition, although Besudil has been included in medical insurance, it is still a relatively newly introduced imported original drug, and domestic production has not yet been fully rolled out. Therefore, there may be differences in drug supply channels, accessibility, and local medical insurance enforcement. It is recommended that patients consult the local medical insurance policy and the drug procurement situation of medical institutions in detail before taking medication to ensure a smooth medication process.

Reference: https://www.drugs.com/pro/rezurock.html